Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas Wins Additional U.S. Indications For Antifungal Mycamine

This article was originally published in PharmAsia News

Executive Summary

Astellas Pharma gained U.S. FDA approval of four new indications for its antifungal Mycamine (micafungin), the firm announced Jan. 22

You may also be interested in...



Astellas Tacrolimus Approval Remains At Bay

Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients

Astellas Tacrolimus Approval Remains At Bay

Astellas Pharma has met with another snag in its attempt to win FDA approval for the once-daily version of its immunosuppressant Prograf (tacrolimus) with receipt of an FDA "approvable" letter for prophylaxis of organ rejection in liver transplant patients

EMEA Recommends Approval For Astellas’ Mycamine

PERTH, Australia - The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended that Astellas Pharma's antifungal Mycamine (micafungin) be approved for candidiasis, Astellas announced Feb. 21

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel